ReviewMycopathologia2021
Pulmonary Talaromycosis: A Window into the Immunopathogenesis of an Endemic Mycosis.
Review in Mycopathologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Glutathione Peroxidase fromInternational journal of molecular sciences · 2026Article
- Recent Advances in the Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Case Report and literature review: X-linked severe combined immunodeficiency complicated byFrontiers in pediatrics · 2026Article
- Cardiovascular system characteristics in HIV/AIDS patients with talaromycosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Pulmonary talaromycosis leads to respiratory failure in an HIV-negative patient in Shandong Province: case report.BMC infectious diseases · 2025Article
- Disseminated Talaromyces marneffei infection presenting as pulmonary cavitary nodules: a case report.BMC infectious diseases · 2025Article
- The dimorphic fungus Talaromyces marneffei: An opportunistic killer in Southeast Asia.PLoS pathogens · 2025Article
- Clinical Characteristics and Prognosis of AIDS Complicated with Talaromycosis marneffei Infection: a Single-Center Retrospective Study.Infectious diseases and therapy · 2025Article
- HIV Complicated with Talaromyces Marneffei Multisystem Infection: A Case Report and Literature Review.Infection and drug resistance · 2025Article
- Clinical characteristics of HIV-associated tracheobronchial Talaromyces marneffei infection in seven patients in Guangxi, China.BMC infectious diseases · 2024Article
- Novel Insights into the Antimicrobial and Antibiofilm Activity of Pyrroloquinoline Quinone (PQQ);Biomolecules · 2024Article
- Metagenomic Next-Generation Sequencing as an Effective Diagnostic Tool for Talaromycosis in HIV-Negative Patients.Mycopathologia · 2024Article
- The microbial damage and host response framework: lesson learned from pathogenic survival trajectories and immunoinflammatory responses ofFrontiers in immunology · 2024Review
- Talaromycosis from Wuhan: two-case report and literature review.Frontiers in cellular and infection microbiology · 2024Review
- Microbiomes Detected by Bronchoalveolar Lavage Fluid Metagenomic Next-Generation Sequencing among HIV-Infected and Uninfected Patients with Pulmonary Infection.Microbiology spectrum · 2023Article
- Impact of pathogen genetics on clinical phenotypes in a population of Talaromyces marneffei from Vietnam.Genetics · 2023Article
- Impact of pathogen genetics on clinical phenotypes in a population ofbioRxiv : the preprint server for biology · 2023Article
- Talaromyces marneffei infection and complicate manifestation of respiratory system in HIV-negative children.BMC pulmonary medicine · 2023Article
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
- Idiopathic non-cirrhotic portal hypertension in a patient with Talaromyces marneffei infection: a case report.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
Talaromycosis is an invasive mycosis caused by the thermally dimorphic saprophytic fungus Talaromyces marneffei (Tm) endemic in Asia. Like other endemic mycoses, talaromycosis occurs predominantly in immunocompromised and, to a lesser extent, immunocompetent hosts. The lungs are the primary portal of entry, and pulmonary manifestations provide a window into the immunopathogenesis of talaromycosis. Failure of alveolar macrophages to destroy Tm results in reticuloendothelial system dissemination and multi-organ disease. Primary or secondary immune defects that reduce CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.